Management of early and advanced colorectal cancer: Therapeutic issues

American Journal of Health-System Pharmacy

Volumn 65, Issue 11 SUPPL. 4, 2008, Pages

  Schwartz, Rowena N ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Age; Antibodies; Antineoplastic agents; Bevacizumab; Colorectal neoplasms; Combined therapy; Toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PANITUMUMAB; TETRACYCLINE;

ADJUVANT THERAPY; ADVANCED CANCER; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DECISION MAKING; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROLYTE DEPLETION; HIGH RISK PATIENT; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEINURIA; RASH; SKIN MANIFESTATION; THROMBOSIS; TREATMENT DURATION; WOUND HEALING IMPAIRMENT;

EID: 44449143487     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080101     Document Type: Conference Paper

References (34)

1. Colon and rectum. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002:113-24.
2. The National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon Cancer version 1.2008. http://www.nccn.org/professionals/ physician_gls/PDF/colon.pdf (accessed 2008 Jan 8).
3. Haller DG, Catalano PJ, Macdonald JS et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD8;vmview=abst_detail_view&confID= 31&abstractID=13235 (accessed 2007 Feb 15).
4. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352:2696-704.
5. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25:102-9.
6. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350:2343-51.
7. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial including survival, with a median follow-up of six years. Presented at American Society of Clinical Oncology meeting. June 1-5, 2007. Abstract 4007.
8. Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005; 23:8671-8.
9. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999; 17:1349-55.
10. Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22:3408-19.
11. Gray RG, Barnwell J, Hills R et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol. 2004; 22(14S suppl):abstract 3501.
12. Benson AB 3rd. New approaches to the adjuvant therapy of colon cancer. Oncologist. 2006; 11:973-80.
13. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345:1091-7.
14. Hershman D, Hall MJ, Wang X et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006; 107:2581-8.
15. O'Neil BH, Goldberg RM. Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can). Semin Oncol. 2005; 32:35-42.
16. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343:905-14.
17. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355:1041-7.
18. de Gramont, Finer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938-47.
19. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18:136-47.
20. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23-30.
21. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-42.
22. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22:229-37.
23. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005; 23(16S suppl):abstract 2.
24. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol. 2006; 24(18S suppl):abstract 3510.
25. Sargent DJ, Goldberg RM, Bleiberg H et al. A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer. J Clin Oncol. 2006; 24(18S suppl):abstract 3517.
26. Pasetto LM, Falci C, Sinigaglia G et al. How many colorectal cancer (CRC) patients older than 70 years may be safely treated with bevacizumab? J Clin Oncol. 2006; 24(18S suppl):abstract 13589.
27. Maindrault-Goebel F, Lledo G, Chibaudel B et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J Clin Oncol. 2006; 24(18S suppl):abstract 3504.
28. Schmoll HJ, Arnold D. Update on capecitabine in colorectal cancer. Oncologist. 2006; 11:1003-9.
29. Avastin package insert. South San Francisco, CA: Genentech, Inc.; 2006 Oct.
30. Erbitux package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006 Mar.
31. Vectibix package insert. Thousand Oaks, CA: Amgen Inc.; 2006 Sep.
32. Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006; 55:657-70.
33. Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10:345-56.
34. Jatoi A, Rowland K, Sloan A et al. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol. 2007; 25(18S suppl):LBA9006.